136 related articles for article (PubMed ID: 32374392)
21. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.
Wolff JM; Scholz A; Boeckmann W; Jakse G
Eur Urol; 1994; 25(4):295-8; discussion 304. PubMed ID: 7519991
[TBL] [Abstract][Full Text] [Related]
22. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
Adedapo KS; Arinola OG; Shittu OB; Kareem OI; Okolo CA; Nwobi LN
Niger J Clin Pract; 2012; 15(3):293-7. PubMed ID: 22960963
[TBL] [Abstract][Full Text] [Related]
24. PSA excess in the differential diagnosis of prostate carcinoma.
Díaz F; Morell M; Rojo G
Arch Esp Urol; 1997 May; 50(4):415-8. PubMed ID: 9219422
[TBL] [Abstract][Full Text] [Related]
25. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
Fukushima K; Satoh T; Baba S; Yamashita K
Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
[TBL] [Abstract][Full Text] [Related]
26. Can salivary creatinine and urea levels be used to diagnose chronic kidney disease in children as accurately as serum creatinine and urea levels? A case-control study.
Renda R
Ren Fail; 2017 Nov; 39(1):452-457. PubMed ID: 28372505
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
28. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
[TBL] [Abstract][Full Text] [Related]
29. Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
Amayo A; Obara W
East Afr Med J; 2004 Jan; 81(1):22-6. PubMed ID: 15080511
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
31. PSMA/PSA ratio evaluated by immunohistochemistry may improve diagnosis of prostate cancer.
Jemaa AB; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
J Immunoassay Immunochem; 2014; 35(1):48-59. PubMed ID: 24063616
[TBL] [Abstract][Full Text] [Related]
32. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
33. [Usefulness of the percentage of free prostatic specific antigen in the differential diagnosis between benign prostatic hyperplasia and prostate cancer].
Gaspar MJ; Arribas I; Hontoria JM; Bokobo P; Coca C; Angulo JC
Med Clin (Barc); 2000 Sep; 115(9):332-6. PubMed ID: 11093893
[TBL] [Abstract][Full Text] [Related]
34. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
35. The clinical utility of measuring free-to-total prostate-specific antigen (PSA) ratio and PSA density in differentiating between benign prostatic hyperplasia and prostate cancer.
Kochañska-Dziurowicz AA; Mielniczuk MR; Stojko A; Kaletka J
Br J Urol; 1998 Jun; 81(6):834-8. PubMed ID: 9666767
[TBL] [Abstract][Full Text] [Related]
36. Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?
Jung K; Stephan C; Lein M; Brux B; Sinha P; Schnorr D; Loening SA
Prostate; 2001 Mar; 46(4):307-10. PubMed ID: 11241553
[TBL] [Abstract][Full Text] [Related]
37. Complexed and total PSA in patients with benign prostatic hyperplasia and prostate cancer.
Tamimi W; Dafterdar R; Mansi M; Alsaad K; Alarifi SA
Br J Biomed Sci; 2010; 67(4):184-8. PubMed ID: 21294445
[TBL] [Abstract][Full Text] [Related]
38. Free and total PSA in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
Tumour Biol; 1997; 18(6):332-40. PubMed ID: 9372866
[TBL] [Abstract][Full Text] [Related]
39. [Clinical significance of PSA-density in differential diagnosis between BPH and early stages prostate cancer].
Uno H
Nihon Hinyokika Gakkai Zasshi; 1995 Dec; 86(12):1776-83. PubMed ID: 8717220
[TBL] [Abstract][Full Text] [Related]
40. Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer.
El Melegy NT; Aboulella HA; Abul-Fadl AM; Mohamed NA
Br J Biomed Sci; 2010; 67(3):109-12. PubMed ID: 20973404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
